Wednesday, June 10, 2026

Patent intelligence · WO

WO 2026060131

ADDITIFS POUR LA PRODUCTION DE VECTEURS VIRAUX

granted A61K/3133
Status granted
Pipeline programs 6
Years to expiry 20
Applicant portfolio 25
Patent details — WO 2026060131

Quick answer

WO 2026060131 (ADDITIFS POUR LA PRODUCTION DE VECTEURS VIRAUX) is held by BIOGEN MA INC [US]. Status: granted. Granted Mar 19, 2026. Expires Mar 14, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
BIOGEN MA INC [US]
Grant date
Expiration
Claims
CPC classes
A61K/3133

More from BIOGEN MA INC [US]

Related pharmaceutical patents in our USPTO index.

  1. WO 2026112397

    COMPOSITIONS ET PROCÉDÉS DE PRODUCTION DE VIRUS ADÉNO-ASSOCIÉS

    BIOGEN MA INC [US] · Expires May 23, 2046

    granted
  2. WO 2026085433

    PROCÉDÉS POUR PRÉPARER DES CONJUGUÉS OLIGONUCLÉOTIDIQUES

    BIOGEN MA INC [US] · Expires Apr 18, 2046

    granted
  3. WO 2026055127

    PROCÉDÉ DE PRODUCTION D'UN MODULATEUR DE RÉCEPTEUR GABA

    SAGE THERAPEUTICS INC A WHOLLY OWNED SUBSIDIARY OF SUPERNUS PHARMACEUTICALS INC [US] · Expires Mar 7, 2046

    granted
  4. WO 2026044005

    PARTICULES DE VAA COMPRENANT DES PEPTIDES CONTENANT RGD POUR ADMINISTRER DES CHARGES UTILES DE DYSTROPHINE

    BIOGEN MA INC [US] · Expires Feb 21, 2046

    granted
  5. WO 2026025082

    MÉTHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER

    BIOGEN MA INC [US] · Expires Jan 24, 2046

    granted
  6. WO 2025207932

    CAPSIDES DE VAA COMPRENANT DES DOMAINES D'ANTICORPS ANTI-TRANSFERRINE

    BIOGEN MA INC [US] · Expires Sep 27, 2045

    granted
  7. WO 2025207959

    ANTICORPS ANTI-RÉCEPTEURS DE LA TRANSFERRINE ET LEURS UTILISATIONS

    BIOGEN MA INC [US] · Expires Sep 27, 2045

    granted

Frequently asked questions

What is US patent 2026060131?

WO 2026060131 (ADDITIFS POUR LA PRODUCTION DE VECTEURS VIRAUX) is held by BIOGEN MA INC [US]. Status: granted. Granted Mar 19, 2026. Expires Mar 14, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.

Who owns WO 2026060131?

BIOGEN MA INC [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.

When does WO 2026060131 expire?

Our index shows an expiration date of Mar 14, 2046 (20 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.